Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Esperion Therapeutics Inc
ESPRCurrent price
2.21 USD
-0.04 USD (-1.78%)
Last closed
2.26 USD
Company
www.esperion.com
ISIN
US29664W1053
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Capitalization
459 091 552 USD
Yield for 12 month
+2.79 %
1Y
3Y
5Y
10Y
15Y
ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Address: 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7.51 USDP/E ratio
–Dividend Yield
–Current Year
+116 334 000 USD
Last Year
+75 475 000 USD
Current Quarter
+51 632 000 USD
Last Quarter
+73 834 000 USD
Current Year
+73 067 000 USD
Last Year
+48 508 000 USD
Current Quarter
+34 346 000 USD
Last Quarter
+58 215 000 USD
Key Figures ESPR
1 year
3 years
5 years
10 years
EBITDA
16 497 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
3.84 %
PEG Ratio
-4.78
Return On Equity TTM
-260.79 %
Wall Street Target Price
7.51 USD
Revenue TTM
295 451 008 USD
Book Value
-1.89 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
52.00 %
Dividend Yield
–
Gross Profit TTM
-70 419 000 USD
Earnings per share
-0.69 USD
Diluted Eps TTM
-0.69 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-29.37 %
Dividend Analytics ESPR
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History ESPR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:6
Payout Ratio
–
Last Split Date
11.06.2013
Dividend Date
–
Stock Valuation ESPR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
1.71
Enterprise Value Revenue
1.97
Price Sales TTM
1.55
Enterprise Value EBITDA
-3.86
Price Book MRQ
98.42
Financials ESPR
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ESPR
For 52 weeks
1.58 USD
3.94 USD
50 Day MA
2.38 USD
Shares Short Prior Month
31 247 976
200 Day MA
2.24 USD
Short Ratio
5.70
Shares Short
30 492 669
Short Percent
15.52 %
BeatStart